Manhattan Scientifics, Inc.
MHTX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.07 | 0.01 | -0.01 |
| FCF Yield | -13.07% | -7.80% | -4.70% | -1.65% |
| EV / EBITDA | -1.24 | -1.63 | -2.45 | 5.43 |
| Quality | ||||
| ROIC | 40.36% | 128.84% | -30.90% | -11.57% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.16 | 0.13 | 0.12 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 0.00% | -19.82% | – |
| Free Cash Flow Growth | 45.56% | 17.10% | -7.40% | -24.05% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.02 | 0.03 | -0.06 |
| Interest Coverage | 0.00 | -32.33 | -26.42 | -27.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -48,545.00 | 0.00 | 2,190.00 | 2,190.00 |